Table 3.

Relationship between discontinuation due to AE and transition to next systemic therapy.

Variables	All patients	Discontinuation due to AE	No discontinuation due to AE	p
End of first-line therapy	307	138	169
Transition to second-therapy (Yes/No)	159/148	42/96	117/52	< 0.001
Conversion rate to second-line therapy	51.8%	30.4%	69.2%	< 0.001
End of second-line therapy	131	59	72
Transition to third-therapy (Yes/No)	46/85	4/55	42/30	< 0.001
Conversion rate to third-line therapy	35.1%	6.7%	58.3%	< 0.001

AE adverse event.